STUDY PROTOCOL

A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol)

Kohei Oashi1*, Taro Shibata2, Kenjiro Namikawa3, Akira Takahashi3, Kenji Yokota4, Eiji Nakano3, Yukiko Teramoto5, Arata Tsutsumida6, Taku Maeda1, Naoya Yamazaki1 and the Dermatologic Oncology Group of the Japan Clinical Oncology Group

Abstract

Background: Paclitaxel is a standard of care for patients with primary cutaneous angiosarcoma of the scalp and face. However, no standard second-line treatment for paclitaxel-resistant patients has ever been established. Since primary cutaneous angiosarcoma expresses a high level of vascular endothelial growth factor receptor, the multitargeted tyrosine kinase inhibitor pazopanib seemed to be the most promising agent, and several retrospective studies have demonstrated its activity against this disease. However, the efficacy and safety of pazopanib in paclitaxel-resistant patients with primary cutaneous angiosarcoma have never been evaluated in a clinical trial.

Methods: In February 2018 the Dermatologic Oncology Group of Japan Clinical Oncology Group started a single-arm confirmatory trial to evaluate the efficacy and safety of pazopanib as a second-line treatment for patients with primary cutaneous angiosarcoma whose disease was resistant to paclitaxel or who were unable to tolerate paclitaxel (JCOG1605, JCOG-PCAS). Patients with primary cutaneous angiosarcoma not associated with lymphedema or radiation, progressing despite first-line paclitaxel monotherapy are included in the study. No prior systemic chemotherapy other than paclitaxel is permitted. Pazopanib is administered orally at an initial dosage of 800 mg once daily. Dose modifications for adverse events are made according to the dose reduction criteria described in the protocol. Treatment is continued until recurrence, disease progression, unacceptable toxic effects, patient refusal, or death. The primary endpoint is progression-free survival, secondary endpoints include overall survival, (Continued on next page)

* Correspondence: oashi@cancer-c.pref.saitama.jp
1Department of Dermatology, Saitama Cancer Center, 780 Komuro, Ina, Kita-ward, Saitama 362-0806, Japan
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Angiosarcomas are extremely rare forms of sarcoma which originate from vascular endothelial cells. The number of patients accounts for 1 to 2% of all soft-tissue and visceral sarcomas [1–4]. Angiosarcomas can be classified into five subtypes, including cutaneous angiosarcoma not associated with lymphedema (primary cutaneous angiosarcoma), cutaneous angiosarcoma associated with lymphedema, radiation-induced cutaneous angiosarcoma, angiosarcoma of deep soft tissue, and angiosarcoma of par enchymal organs [5]. They are regarded as closely related tumors which share similar pathological features rather than a single entity. Primary cutaneous angiosarcoma is the most frequent subtype of angiosarcoma which accounts for about 28% of all angiosarcoma patients. Primary cutaneous angiosarcoma typically develops in the head and neck region, especially in the scalp and upper face of elderly men. Angiosarcoma of the head and neck region has a poor prognosis with reported 5 year survival rates of 11 to 53% [1, 3, 4, 6–10].

The standard of care for localized cutaneous angiosarcoma in Western countries is radical surgery combined with adjuvant radiation therapy (RT) [11, 12]. Since Japanese patients tend to present with larger primary tumors and a poorer prognosis in comparison with Caucasian patients [1, 5, 13–15], systemic chemotherapy (adjuvant and/or neoadjuvant) in combination with local treatment can be a viable option for Japanese patients [16].

Although doxorubicin has been a key drug in the treatment of metastatic and unresectable soft tissue sarcomas [17], since paclitaxel has been shown to be more effective against primary cutaneous angiosarcoma of the scalp and face [2, 18, 19], multimodal treatment, including local treatment and chemotherapy with paclitaxel has become a standard of care for Japanese patients with locoregional primary cutaneous angiosarcoma of the scalp and face. Because systemic chemotherapy with paclitaxel is also a first-line treatment for patients with distant metastasis, paclitaxel is administered to Japanese patients with primary cutaneous angiosarcoma as an initial treatment regardless of the extent of their disease. However, no standard second-line treatment for paclitaxel-resistant patients has ever been established, and the prognosis of such patients is dismal.

The recent development of molecular targeted therapy for cancer has resulted in the availability of many potential drugs for the treatment of primary cutaneous angiosarcoma [20–22]. In addition to molecular targeted therapies, several new cytotoxic agents, including eribulin and trabectedin, have shown to be effective in the treatment of advanced sarcoma [23, 24]. Unfortunately, these clinical trials have seldom or never included patients with primary cutaneous angiosarcoma, and thus a new clinical trial focusing on primary cutaneous angiosarcoma alone has been needed to evaluate the efficacy of these new drugs. Since primary cutaneous angiosarcoma expresses a high level of vascular endothelial growth factor receptor (VEGFR) [25, 26], the multitargeted tyrosine kinase inhibitor pazopanib, which blocks VEGFR-1, 2, and 3, the platelet-derived growth factor receptor (PDGFR), and c-Kit, seemed to be the most promising agent [27], and several retrospective studies have demonstrated its activity against this disease [28–32]. However, the efficacy and safety of pazopanib in patients with primary cutaneous angiosarcoma have never been evaluated in a clinical trial.

In February 2018, the Dermatologic Oncology Group of Japan Clinical Oncology Group (JCOG) therefore started a single-arm confirmatory trial to evaluate the efficacy and safety of pazopanib as a second-line treatment for patients with primary cutaneous angiosarcoma whose disease was resistant to paclitaxel or who were unable to tolerate paclitaxel (JCOG1605, JCOG-PCAS).

Methods / design
Aim
The purpose of this study is to evaluate the efficacy and safety of pazopanib as a second-line treatment
for patients with primary cutaneous angiosarcoma after failure of first-line paclitaxel.

**Study setting**
A multi-institutional, single-arm, open-label, confirmatory trial.

**Funding**
This study is supported in part by the National Cancer Center Research and Development Fund of Japan (2020-J-3).

**Endpoints**
The primary endpoint is progression-free survival (PFS). PFS is defined as the time from registration to either the first event of tumor progression or death from any cause, and it is censored at the latest day when the patient is alive without any evidence of progression.

The secondary endpoints are overall survival (OS), response rate (RR), disease control rate (DCR), adverse events (AEs), and serious adverse events (SAEs). OS is defined as the time from registration to death from any cause, and it is censored at the last day the patient is known to be alive. RR is defined as the proportion of patients whose best overall response without confirmation is complete response (CR) or a partial response (PR) out of patients with measurable lesion at the baseline. Patient response is measured in accordance with the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). DCR is defined as the proportion of patients whose best overall response without confirmation is CR, PR, or stable disease (SD) out of patients with measurable lesion at the baseline. AEs are evaluated according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0). SAE is defined as any ≥grade 4 non-hematologic toxicity at least possibly related to treatment, death from any cause during treatment or within 30 days after the last administration, and treatment-related death.

**Inclusion criteria**
1) Histologically confirmed primary cutaneous angiosarcoma that is not associated with lymphedema or a history of radiation exposure.
2) Primary or metastatic lesions (histological evaluation is not essential for metastatic lesions).
3) Absence of intracranial metastasis.
4) Age between 20 years and 85 years old.
5) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
6) Past history of paclitaxel monotherapy as a first-line treatment in combination with or not in combination with any local treatment (surgery and/ or radiation therapy).
7) No past history of any systemic chemotherapy other than paclitaxel.
8) Resistance or intolerance to paclitaxel.
9) A measurable lesion is not required.
10) No prior use of antiangiogenic agents.
11) Absence of any non-healing wound.
12) Adequate organ and marrow function as defined below within 14 days prior to enrollment:
   a) Absolute neutrophil count ≥ 1500/mm³.
   b) Hemoglobin ≥ 9.0 g/dL.
   c) Platelet count ≥ 10 × 10⁴/mm³.
   d) Total bilirubin ≤ 2.25 mg/dL.
   e) Aspartate aminotransferase ≤ 75 U/L.
   f) Alanine aminotransferase, male: ≤ 105 U/L, female: ≤ 57.5 U/L.
   g) Renal function: serum creatinine ≤ 1.5 mg/dL, or, if > 1.5 mg/dL, calculated creatinine clearance > 50 mL/min.
   h) Prothrombin time-international normalized ratio ≤ 1.38.
   i) Activated partial thromboplastin time ≤ 44.4 s.
   j) Thyroid-stimulating hormone: 0.5–4.5 μU/mL.
   k) Free triiodothyronine: 2.0–4.0 pg/mL.
   l) Free thyroxine: 0.9–1.8 ng/dL.
   m) Left ventricular ejection fraction ≥ 50%.
   n) Corrected QT interval ≤ 480 ms.
   o) Negative urinary protein, or, if not negative, 24-h urinary protein excretion ≤ 0.15 g (urinary protein/creatinine ratio ≤ 0.15 g/gCr is permitted).
13) Written informed consent.

**Exclusion criteria**
1) A synchronous or metachronous (within 3 years) malignancy except for carcinoma in situ or intramucosal tumors curatively treated by local therapy with a 5-year survival of over 95%.
2) Active infection requiring systemic therapy.
3) Body temperature ≥ 38 degrees Celsius.
4) Pregnant, possibly pregnant, or lactating women. Within 28 days after childbirth. Men favoring gestation of their partners.
5) Severe psychiatric disease.
6) Current systemic administration of a steroid or other immunosuppressant.
7) Hypertension (> 140 mmHg systolic and > 90 mmHg diastolic) that cannot be adequately controlled with antihypertensive treatments.
8) Any cardiovascular disease or procedure listed below within 6 months prior to enrollment:
   a) Percutaneous transluminal coronary angioplasty.
   b) Myocardial infarction.
Interim analysis and monitoring
We plan to conduct futility analyses to judge whether the study should be terminated early due to futility. The futility analyses will be conducted after half of the planned number patients have been enrolled. If the upper limit of the 95% confidence interval (CI) of the median PFS is less than the expected value, a decision on the study termination will be made via a comprehensive review at that time. The JCOG Data Center staff and the Study Coordinator will conduct central monitoring issuing a monitoring report at least every 1 year to evaluate and improve study progress, data integrity and patient safety. Futility will be considered at each monitoring report if necessary. For quality assurance, site-visit audits, not for a study-specific basis but for the study group basis, will be performed by the JCOG Audit Committee.

Discussion
The aim of this study is to evaluate the efficacy and safety of pazopanib as a second-line treatment for patients with primary cutaneous angiosarcoma after failure of first-line paclitaxel. If the primary endpoint is met, pazopanib will be regarded as a standard of care for paclitaxel-resistant patients for whom no standard second-line treatment is established. This study is designed as a single arm trial considering rarity of disease. Given the fact that expected and threshold value of primary endpoint was set according to robust historical control data (unpublished), we position this study as a confirmatory trial.

Abbreviations
RT: Radiation therapy; VEGFR: Vascular endothelial growth factor receptor; PDGFR: Platelet-derived growth factor receptor; JCOG: Japan Clinical Oncology Group; PFS: Progression-free survival; OS: Overall survival; RR: Response rate; DCR: Disease control rate; AE: Adverse events; SAE: Serious adverse events; CR: Complete response; PR: Partial response; RECIST: Response Evaluation Criteria in Solid Tumors; CTCAE: Common Terminology Criteria for Adverse Events; ECOG: Eastern Cooperative Oncology Group; JCOG: The Japan Clinical Oncology Group; CI: Confidence interval; CT: Computed tomography

Acknowledgements
We would like to thank all members of JCOG Data Center/Operation office and JCOG Dermatologic Oncology Group.

Authors’ contributions
KO, as a corresponding author, proposed the concept and idea for JCOG1605 study, drafted the protocol design of the study and wrote the manuscript. TS contributed to the design and logistics of the protocol, proofread the manuscript, and will undertake statistical analysis. KN, AT, KY, EN, YT, AT and TM were in charge of registering the trial protocol to the review boards of each participating institution and proof-read the manuscript. NY proposed the concept and idea for JCOG1605, contributed to the design and logistics of the protocol and proof-read the manuscript, and conducted the initiation of the study. All authors critically revised the manuscript for intellectual content and approved the final manuscript.

Funding
This study was supported in part by the National Cancer Center Research and Development Fund of Japan (2020-J-3). The role of the funders is to provide financial support for management office, aid in the development of the electronic data capturing system, and to conduct meetings. The National Cancer Center Research and Development peer reviewed the study protocol and monitored research progress.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analysed at the time of submission.

Ethics approval and consent to participate
This study is being conducted in accordance with the principles expressed in the Declaration of Helsinki, Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects and SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. The study protocol was approved by the JCOG Protocol Review Committee in December 2017 and by the Institutional Review Board of National Cancer Center Hospital on February 9th, 2018. Written informed consent has been obtained from all enrolled participants. At the time of submission (June 2020), a total of 21 institutions are participating in this trial. The participating institutions are as follows: Hokkaido University Hospital, Ashihara Medical University Hospital, Sapporo Medical University School of Medicine, University of Tsukuba, Saitama Medical University International Medical Center, Saitama Medical University, National Cancer Center Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Keio University Hospital, The University of Tokyo Hospital, Niigata Cancer Center Hospital, Toyama Prefectural Central Hospital, Shinshu University School of Medicine, Shizuoka Cancer Center, Nagoya University School of Medicine, Kyoto University Hospital, Osaka International Cancer Institute, Faculty of Medicine, Fukuoka University, Kyushu University Hospital, Kumamoto University Hospital and National Hospital Organization Kagoshima Medical Center.

Consent for publication
Not applicable.

Competing interests
Dr. Namikawa has received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis Pharmaceutical, Toray Industries, TaKara Bio, Eisai, and Chugai Pharmaceutical, unrelated to the submitted work.

Dr. Tsutsumida has received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis Pharmaceutical, unrelated to the submitted work.

Dr. Takahashi has received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Merck Sharp & Dohme, and Novartis Pharmaceutical, unrelated to the submitted work.

Dr. Yamazaki has received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis Pharmaceutical, Takeda Pharmaceutical, and Chugai Pharmaceutical, unrelated to the submitted work.

Author details
1Department of Dermatology, Saitama Cancer Center, 780 Komuro, Iina, Kita-Adachi-gun, Saitama 362-0806, Japan. 2JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan. 3Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. 4Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 5Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan. 6Department of Dermatologic Oncology, Dermatology, Cancer Institute Hospital, Tokyo, Japan. 7Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine Hokkaido University, Sapporo, Japan.

Received: 3 June 2020 Accepted: 2 July 2020
Published online: 13 July 2020

References
1. Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer. 1987;59(5):1046–57.
2. Fata F, O'Reilly E, Ison D, Pfister D, Leffel D, Kelsen D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86(10):2034–7.
3. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11(3):241–7.
4. Goldblum JR, Folpe AS, Weiss SW, Enzinger FM. Enzinger and Weiss’s soft tissue tumors. 6th ed. Philadelphia: Saunders/Elevevier; 2014.
5. Oashi K, Namikawa K, Tsutsumida A, Takahashi A, Itami J, Igaki H, et al. Surgery with curative intent is associated with prolonged survival in patients with cutaneous angiosarcoma of the scalp and face - a retrospective study of 38 untreated cases in the Japanese population. Eur J Surg Oncol. 2018;44(6):823.
6. Mark RJ, Poen JC, Tran LM, Fu YS, Yu JS, Julillard GF. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996;77(11):2400–6.
7. Latay G, Dhuka AR, Hallez H, Xiao L, Zou C, Smith KD, et al. Angiosarcoma: clinical and molecular insights. Ann Surg. 2010;251(6):1098–106.
8. Lydatt WM, Shah A, Shah JP. Angiosarcoma of the head and neck. Am J Surg. 1994;168(3):451–4.
9. Dettenborn T, Wermker K, Schulze HJ, Klein M, Schwipper V, Hallermann C. Prognostic features in angiosarcoma of the head and neck: a retrospective monocentric study. J Craniofac Surg. 2014;25(8):1623–8.
10. Shin JY, Roh SG, Lee NH, Yang KM. Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: systematic review and meta-analysis. Head Neck. 2017;39(2):380–6.
11. Penel N, Lansiaux A, Denis C, Angiosarcomas and taxanes. Curr Treat Options in Oncol. 2007;8(6):428–34.
12. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11(10):983–91.
13. Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003;98(8):1716–26.
14. Morgan MB, Swann S, Somach S, Eng W, Smoller B. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol. 2004;50(6):867–74.
15. Trofymenko O, Curiel-Lewandrowski C. Surgical treatment associated with improved survival in patients with cutaneous angiosarcoma. J Eur Acad Dermatol Venereol. 2018;32(11):2893–301.
16. Fujisawa Y, Yoshino K, Fujimura T, Nakamura Y, Okiyama N, Ishitsuka Y, et al. Cutaneous Angiosarcoma: the possibility of new treatment options especially for patients with large primary tumor. Front Oncol. 2018;8:486.
17. Tap W, Jones R, Van Tine B, Chmeliweski B, Elas A, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488–97.
18. Penel N, Bui BN, Bay JD, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26(3):5269–74.
19. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, et al. Paclitaxel in patients with advanced angiosarcoma: a phase II trial from the French sarcoma group (GSF/GETO). Oncologist. 2012;17(2):243–6.
20. Aguilnik M, Barter HL, Okuno SH, von Mehren M, Jovanovic BD, Brodskiy BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendothelioma. Ann Oncol. 2013;24(1):257–63.
21. Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreur C, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French sarcoma group (GSF/GETO). Oncologist. 2012;17(2):260–6.
22. Koontz BF, Miles EF, Rubio MA, Madden JD, Fisher SR, Scher RL, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck. 2008;30(2):262–6.
23. Scholspi F, Chawla S, Mali R, Italiano A, Gelderblom H, Choy E, et al. ErbB1 versus dacarbazime in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomized, open-label, multicentre, phase 3 trial. Lancet (British edition). 2016;387(10028):1629–37.
24. Hensley M, Patel S, von Mehren M, Ganjoo K, Jones R, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine in patients with advanced angiosarcoma of soft tissue: an open-label phase 1b trial. Lancet Oncol. 2013;14(4):388–97.
25. Yonemori K, Tsuta K, Ando M, Hirakawa A, Hatanaka Y, Matsuno Y, et al. Contrasting prognostic implications of platelet-derived growth factor
receptor-beta and vascular endothelial growth factor receptor-2 in patients with angiosarcoma. Ann Surg Oncol. 2011;18(10):2841–50.
27. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.
28. Tomita H, Koike Y, Asai M, Ogawa F, Abe K, Tanioka M, et al. Angiosarcoma of the scalp successfully treated with pazopanib. J Am Acad Dermatol. 2014;70(1):e19–21.
29. Kitamura S, Hata H, Imafuku K, Haga N, Homma E, Shimizu H. Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma. Clin Exp Dermatol. 2015;40(8):931–3.
30. Fujiwara S, Nagai H, Nakamachi Y, Kawano S, Nishigori C. Refractory metastasis of cutaneous angiosarcoma showing complete response to pazopanib. Eur J Dermatol. 2015;25(1):71–3.
31. Miura H, Shirai H. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma. Clin Exp Dermatol. 2015;40(5):575–7.
32. Ogata D, Yanagisawa H, Suzuki K, Oashi K, Yamazaki N, Tsuchida T. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma. Med Oncol. 2016;33(10):116.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.